The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Recurrent Depression With Vagus Nerve Stimulation

To the Editor: Vagus nerve stimulation has proved to be an effective treatment for certain forms of epilepsy (15) and is presently being investigated as a form of therapy for depressive disorders that are refractory to conventional treatments (6). Following is a case in which a patient, successfully treated for epilepsy with a vagus nerve stimulator, developed a recurrence of depression requiring medication intervention.

Mr. A was a 49-year-old Caucasian man who was admitted to a residential treatment facility in 1981. His medical background revealed a history of meningitis at age 1.5 years, with subsequent development of severe seizure disorder, developmental delay, and mental retardation. He was treated at our facility with combination antiepileptic drug therapy with limited success, and he developed the complication of drug-induced hyponatremia. He was successfully implanted with a Cyberonics Model 100 NCP Pulse Generator in 1999.

In the next year, while still following his anticonvulsant medication regimen, he realized a 30% reduction in the number of seizures and an overall improvement in scores on measures of quality of life. However, he was admitted twice to the infirmary for a high level of passivity, withdrawal from others, diminished eye contact, and refusal to be involved in routine activities. He was nonverbal, had a diminished appetite, and exhibited weight loss, a subdued affect, and psychomotor retardation. The results of laboratory studies were unremarkable. His sodium level was 137 meq/liter; his phenytoin and carbamazepine levels were 13 μg/ml and 7 μg/ml, respectively. There was no apparent increase in his seizure activity.

A review of his records revealed a history of similar episodes diagnosed as depression in 1982, 1984, 1987, 1990, and 1994; all were treated with amitriptyline, 75 mg/day, with apparently good results. There were no documented episodes of mania, and Mr. A’s mother knew of no family history of affective illness. During his most recent episode, Mr. A began treatment with extended-release venlafaxine, 37.5 mg/day, graduated increased to 75 mg/day, with good results. He ultimately returned to his cottage for further care after several weeks. The results of a follow-up examination showed him to be verbal, responsive to the examiner, eating well, and engaged in his usual daily activities.

This case is an example of a seeming lack of effective prophylaxis of recurrent episodes of depression in a patient with a vagus nerve stimulator implant. Although vagus nerve stimulation may prove an effective adjunctive treatment for refractory depression, further clarification seems necessary to identify its specific role in the treatment of affective disease.

References

1. Penry JK, Dean JC: Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia 1990; 31(suppl 2):S40–S43Google Scholar

2. Uthman BM, Wilder BJ, Hammond EJ, Reid SA: Efficacy and safety of vagus nerve stimulation in patients with complex partial seizures. Epilepsia 1990; 31(suppl 2):S44–S50Google Scholar

3. Uthman BM, Wilder BJ, Penry JK, Dean C, Ramsay RE, Reid SA, Hammond EF, Tarver WB, Wernicke JF: Treatment of epilepsy by stimulation of the vagus nerve. Neurology 1993; 43:1338–1345Google Scholar

4. The Vagus Nerve Stimulation Study Group: A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 1995; 45:224–230Crossref, MedlineGoogle Scholar

5. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheless JW: Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998; 51:48–55Crossref, MedlineGoogle Scholar

6. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK, Goodman R: Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000; 47:276–286Crossref, MedlineGoogle Scholar